Webinar: From Research to Transforming Patients' Lives
Congenica founders celebrate a decade of innovation
Professor Matthew Hurles discusses the Deciphering Developmental Disorders study
Congenica awarded European contract to develop NGS analysis workflow in oncology
Congenica announces Early Access Program for its novel Precision Oncology Solution
Transforming Cancer Care at ESHG 2023
Satellite Symposium from ESHG 2023 featuring Andrew Biankin and Philip Beer who discuss what's needed to transform cancer care today
Driving Precision Medicine
Who we are
We are a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale.
We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide.
Congenica was founded on pioneering work at the Wellcome Sanger Institute and the UK NHS. Our products combine state-of-the-art technology, market-leading automation and Artificial Intelligence to enable our uniquely differentiated platform to be employed in all areas of human disease where genomic information is key to unlock actionable insights.
Full automation with powerful APIs and ML to reduce burden on specialist staff, maximise case throughput, accelerate decision-making and streamline reporting
CE-IVD approved software
Certified, accurate and secure analysis platform to support clinical decisions with the highest degree of confidence in the clinical outcome
From gene panels to whole genomes, SaaS or on premise, we offer ultimate flexibility to support all customer needs
APIs designed to be compatible with existing workflow solutions, LIMS systems and EHRs for optimised operational efficiency
Our Products and Services
Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance. Our platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care.
At Congenica, we understand how to transform complex genetic data into actionable insights to drive precision medicine at scale
Rob Denison CEO Congenica